- Home
- SNT vs IRWD Comparison
SNT vs IRWD Comparison
Compare SNT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- IRWD
- Stock Information
- Founded
- SNT 1965
- IRWD 1998
- Country
- SNT Canada
- IRWD United States
- Employees
- SNT N/A
- IRWD N/A
- Industry
- SNT Telecommunications Equipment
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- IRWD Health Care
- Exchange
- SNT Nasdaq
- IRWD Nasdaq
- Market Cap
- SNT 95.2M
- IRWD 111.2M
- IPO Year
- SNT 1993
- IRWD 2010
- Fundamental
- Price
- SNT $4.42
- IRWD $1.11
- Analyst Decision
- SNT
- IRWD Buy
- Analyst Count
- SNT 0
- IRWD 5
- Target Price
- SNT N/A
- IRWD $4.94
- AVG Volume (30 Days)
- SNT 52.9K
- IRWD 1.4M
- Earning Date
- SNT 08-25-2025
- IRWD 11-06-2025
- Dividend Yield
- SNT N/A
- IRWD N/A
- EPS Growth
- SNT N/A
- IRWD N/A
- EPS
- SNT 0.22
- IRWD N/A
- Revenue
- SNT $38,038,000.00
- IRWD $308,519,000.00
- Revenue This Year
- SNT N/A
- IRWD N/A
- Revenue Next Year
- SNT N/A
- IRWD N/A
- P/E Ratio
- SNT $19.64
- IRWD N/A
- Revenue Growth
- SNT 12.79
- IRWD N/A
- 52 Week Low
- SNT $1.40
- IRWD $0.53
- 52 Week High
- SNT $5.04
- IRWD $5.13
- Technical
- Relative Strength Index (RSI)
- SNT 51.08
- IRWD 51.15
- Support Level
- SNT $4.25
- IRWD $1.01
- Resistance Level
- SNT $4.54
- IRWD $1.35
- Average True Range (ATR)
- SNT 0.24
- IRWD 0.09
- MACD
- SNT -0.00
- IRWD -0.03
- Stochastic Oscillator
- SNT 37.65
- IRWD 27.78
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.